RESEARCH TRIANGLE PARK, N.C., May 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (“G1” or the “Company”), a clinical-stage oncology company, today announced the commencement of the initial public offering of shares of its common stock pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “Commission”). The offering consists of 6,250,000 shares of common stock being offered by the Company. In addition, the Company is expected to grant the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price, less the underwriting discount. The current expected initial public offering price is between $15.00 and $17.00 per share. G1 plans to list its common stock on the NASDAQ Global Market under the ticker symbol “GTHX”.
The Company intends to use the net proceeds from the offering to fund the development of its two clinical-stage product candidates and a preclinical-stage product candidate, for drug manufacturing expenses, and for working capital and other general corporate purposes.
J.P. Morgan Securities LLC and Cowen and Company, LLC will serve as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. will serve as co-managers.
This offering will be made only by means of a prospectus. A copy of the preliminary prospectus can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by calling (631) 274-2806 or by faxing (631) 254-7140.
The registration statement relating to these securities has been filed with the Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
This press release contains certain forward-looking statements, including statements with regard to G1’s proposed initial public offering. Words such as “expects”, “anticipates” and “intends” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no assurance can be given that the initial public offering discussed above will be completed on the terms described. Completion of the proposed initial public offering and the terms thereof are subject to numerous factors, many of which are beyond the control of the Company, including, without limitation, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus included in the registration statement, in the form last filed with the Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.
CONTACT: Investors: Robert Uhl Westwicke Partners 858-356-5932 email@example.com Media: Laura Bagby 6 Degrees Communications 312-448-8098 firstname.lastname@example.org